Akari Therapeutics Plc (AKTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 24 WEST 40TH STREET
NEW YORK, NY 10018
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments68,919,99578,772,8882,718,0004,016,000 
Cash and cash equivalents68,919,99578,772,8882,718,0004,016,000 
Restricted cash and investments   142,000142,000 
Receivables10,366    
Other undisclosed current assets728,126166,14160,000115,000 
Total current assets:69,658,48778,939,0292,920,0004,273,000 
Noncurrent Assets
Property, plant and equipment40,51334,93240,00044,000 
Intangible assets, net (including goodwill)52,48319,341,379   
Goodwill  19,283,280   
Intangible assets, net (excluding goodwill)52,48358,099   
Restricted cash and investments142,079    
Other undisclosed noncurrent assets  (19,141,201)   
Total noncurrent assets:235,075235,11040,00044,000 
TOTAL ASSETS:69,893,56279,174,1392,960,0004,317,000 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,728,8107,599,446960,000910,000 
Accounts payable4,320,5883,753,518960,000910,000 
Accrued liabilities408,2223,845,928   
Due to related parties  3,031,304   
Other undisclosed current liabilities16,396,15827,165,905   
Total current liabilities:21,124,96837,796,655960,000910,000 
Noncurrent Liabilities
Liabilities, other than long-term debt   43,00038,000 
Other liabilities   43,00038,000 
Other undisclosed noncurrent liabilities49,06946,038984,000774,000 
Total noncurrent liabilities:49,06946,0381,027,000812,000 
Total liabilities:21,174,03737,842,6931,987,0001,722,000 
Equity
Equity, attributable to parent48,719,52541,331,446973,0002,595,000 
Common stock18,340,89418,340,894927,000927,000 
Additional paid in capital87,018,76486,062,36434,224,00034,175,000 
Accumulated other comprehensive income (loss)156,480197,091   
Accumulated deficit(56,796,613)(63,268,903)(34,178,000)(32,507,000) 
Total equity:48,719,52541,331,446973,0002,595,000 
TOTAL LIABILITIES AND EQUITY:69,893,56279,174,1392,960,0004,317,000 

Income Statement (P&L) (USD)

3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
Gross profit:22,973,138(22,973,138)   
Operating expenses(4,290,950)(23,326,979)(1,456,000)(2,342,000) 
Other undisclosed operating income (loss)(22,973,138)22,973,138   
Operating loss:(4,290,950)(23,326,979)(1,456,000)(2,342,000) 
Nonoperating income (expense)10,763,240(25,408,711)(215,000)(535,000) 
Gain (loss), foreign currency transaction, before tax(30,007)(22)   
Other nonoperating expense   (215,000)(535,000) 
Interest and debt expense5,950(3,054,262)   
Income (loss) from continuing operations before equity method investments, income taxes:6,478,240(51,789,952)(1,671,000)(2,877,000) 
Other undisclosed income (loss) from continuing operations before income taxes(5,950)3,054,262   
Income (loss) from continuing operations before income taxes:6,472,290(48,735,690)(1,671,000)(2,877,000) 
Income tax benefit    560,000 
Income (loss) from continuing operations:6,472,290(48,735,690)(1,671,000)(2,317,000) 
Income (loss) before gain (loss) on sale of properties:6,472,290(48,735,690)(1,671,000)(2,317,000) 
Net income (loss) available to common stockholders, diluted:6,472,290(48,735,690)(1,671,000)(2,317,000) 

Comprehensive Income (USD)

3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
Net income (loss):6,472,290(48,735,690)(1,671,000)(2,317,000) 
Other comprehensive loss   (1,671,000)  
Comprehensive income (loss):6,472,290(48,735,690)(3,342,000)(2,317,000) 
Other undisclosed comprehensive loss, net of tax, attributable to parent(40,611)(43,262)   
Comprehensive income (loss), net of tax, attributable to parent:6,431,679(48,778,952)(3,342,000)(2,317,000) 

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: